Menu
The IDIR test detects and quantifies insulin resistance, a common risk factor for cardiometabolic diseases present up to a decade before the onset of symptoms. Insulin resistance can be reversed through non-drug, educational and medical therapies, making it possible to delay or even prevent type 2 diabetes, cardiovascular disease and other cardiometabolic diseases. Insulin resistance currently affects between 15.5% and 46.5% of the world's population.
By detecting insulin resistance reliably, rapidly and non-invasively, the IDIR test meets an unmet need: to know the metabolic health status of populations at a very early stage in the onset of disease. The IDIR test is a revolutionary urine test developed by the Sys2Diag Joint Research Unit (CNRS-ALCEN) and SkillCell, The IDIR test detects and quantifies insulin resistance, a common risk factor for cardiometabolic diseases present up to a decade before the onset of symptoms. Insulin resistance can be reversed through non-drug, educational and medical therapies, making it possible to delay or even prevent type 2 diabetes, cardiovascular disease and other cardiometabolic diseases. Insulin resistance currently affects between 15.5% and 46.5% of the world's population. By detecting insulin resistance reliably, rapidly and non-invasively, the IDIR test meets an unmet need: to know the metabolic health status of populations at a very early stage in the onset of disease. The IDIR test is a revolutionary urine test developed by the Sys2Diag Joint Research Unit (CNRS-ALCEN) and SkillCell, using a patented technology based on the enzymatic assay of branched-chain amino acids (BCAAs). The IDIR test is designed to measure abnormal levels of BCAAs in urine, levels which are correlated with insulin resistance. According to numerous scientific studies, BCAAs are considered to be the earliest metabolic biomarkers of insulin resistance, a key risk factor for cardiometabolic diseases. What's more, it's crucial to stress that, once detected in time, insulin resistance can be reversible for a window of 10 to 15 years.
The IDIR test stands out for its simplicity and non-invasiveness, offering an affordable solution compared with existing methods (HOMA IR, etc.). The effectiveness of the IDIR® test has been proven by a validation study involving 330 patients in France, soon to be published in The Lancet. This study demonstrates its high level of accuracy and reliability. The device is CE marked and ANSM registered, attesting to its compliance with the most stringent European standards.
Compared with current methods for assessing insulin resistance, the IDIR test offers a promising alternative. The test requires a single urine sample and provides results in just one hour. The IDIR® test thus makes mass screening for insulin resistance possible, and provides an innovative and practical tool for the prevention of cardiometabolic diseases.
The IDIR test stands out as a world first in screening for insulin resistance. Its features include :
Non-invasive nature: the test, performed on a urine sample, guarantees simple deployment and an uncomfortable experience for the patient.
Precise quantification: Thanks to its quantitative nature, IDIR® makes it possible to monitor the evolution of insulin resistance and objectify the impact of changes in real time.
Speed: Up to 45 urine samples can be analyzed simultaneously, with results in 60 minutes, combining efficiency and speed.
Easy to use: IDIR® requires limited technical equipment. It can be set up in any biological analysis laboratory or point-of-care facility.
Affordability: IDIR® represents an attractive economic solution compared with existing blood tests.
INNOV BIOTECH SAS Au capital de 1 000 € 75012 PARIS RCS 894 484 146
INNOV BIOTECH SAS Au capital de 1 000 € 75012 PARIS RCS 894484146
